share_log

4DMT Extends Cash Runway To 2028 With $506M, Plans Phase 3 Trials For 4FRONT-1 & 4FRONT-2 In Wet AMD, Develops Early-Stage DME And CF, Explores Partnerships And Strategic Financing

Benzinga ·  Jan 10 21:03
  • Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosis
  • After alignment with FDA and EMA on trial designs for the 4D-150 Phase 3 4FRONT program in wet AMD, 4FRONT-1 and 4FRONT-2 trials on track to initiate in Q1 2025 and Q3 2025 respectively
  • Primary endpoint 52-week topline data for both 4FRONT-1 and 4FRONT-2 expected in H2 2027
  • Cash runway extended under updated operating plan; unaudited cash, cash equivalents and marketable securities of $506M as of December 31, 2024 expected to fund operations into 2028

EMERYVILLE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company))), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced a strategically focused pipeline, updated Phase 3 4FRONT program plans, initial 4FRONT guidance and resulting updated cash runway guidance.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment